Product Overview
[Drug Name]
Trade Name: Shuliqineng
English Name: Trimebutine Maleate Tablets
Chinese Pinyin: Malaisuanqumeibuting Pian
[Ingredients]
The main ingredient of this product is trimebutine maleate.
[Properties]
Appears as white crystals or crystalline powder, odorless, with a bitter taste. It is highly soluble in formic acid, easily soluble in glacial acetic acid and chloroform, soluble in methanol and acetonitrile, and poorly soluble in water.
[Indications]
Indicated for relief of symptoms such as loss of appetite, nausea, vomiting, belching, abdominal distension, abdominal pain, diarrhea, and constipation caused by gastrointestinal disorders. It can also be used for irritable bowel syndrome.
[Dosage and Administration]
For adults, take orally: 0.1-0.2g three times a day. The dose may be increased or decreased based on age and symptoms, or as directed by a physician.
[Adverse Reactions]
Occasional reactions include thirst, oral numbness, abdominal borborygmi, abdominal distension, constipation, tachycardia, drowsiness, dizziness, headache, rash, and elevated aspartate aminotransferase and alanine aminotransferase levels, with an incidence of approximately 0.4%.
[Contraindications]
Contraindicated in patients with allergies to trimebutine maleate.
[Precautions]
Patients who develop a rash should discontinue the drug and observe the patient's condition.
[Use in Special Populations]
Precautions for Children: Use with caution in children.
Precautions for Pregnancy and Lactation: Use with caution in pregnant and lactating women.
Precautions for the Elderly: Elderly individuals generally have weaker physiological functions, so a reduced dosage is recommended.
[Drug Interactions]
Not yet known.
[Pharmacological Actions]
1. Bidirectional regulatory effect on gastrointestinal smooth muscle: This product non-competitively inhibits the contraction induced by acetylcholine. In patients with digestive system diseases, intravenous injection of 1 mg/kg of this product has been found to regulate the movement of the hypermotility muscles of the stomach, regularizing irregular gastric movements. Intrajejunal administration of 4-6 mg/kg has been found to induce physiological digestive tract propulsive movement in adults. In patients with neostigmine-induced hypermotility, 50 mg intravenously can inhibit motility in the ileum, ascending colon, and sigmoid colon to pre-load levels. 2. Gastrointestinal analgesic effect: This product can also activate peripheral K opioid receptors, releasing gastrointestinal peptides such as motilin, vasoactive intestinal peptide, and gastrin, thereby inhibiting visceral nerve reflexes, blocking gastrointestinal afferent nerves, reducing the effects of peripheral noxious stimuli on the central nervous system, raising the visceral pain threshold under pathophysiological conditions, and alleviating abdominal pain symptoms. 3. Peripheral antiemetic effect: Animal studies have shown that this product has a weak inhibitory effect on apomorphine-induced vomiting. However, for vomiting induced by copper sulfate, intravenous injection of 3 mg/kg or oral administration of 60 mg/kg can significantly prolong the time required to induce vomiting.
[Storage]
Store at room temperature.
[Strength]
0.1 g
[Packaging]
Aluminum-plastic blister pack, 20 tablets per box.
[Validity Period]
36 months
[Approval Number]
National Medicine Standard H20030290
[Manufacturer]
Tianjin Tiabian Pharmaceutical Co., Ltd.
